EARS
Altamira Therapeutics Ltd.
Set alert
52-week range unavailable
- Open
- 3.08
- Prev close
- 3.05
- Mkt cap
- 39.19M
- Vol
- 174.07K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.00
- High
- 3.09
- Forward P/E
- -0.72
- Beta
- 1.40
- Short ratio
- 0.08
- Inst. own
- 5.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 31, 2021
- 50-d avg
- 3.25
- 200-d avg
- 3.41
- 1y target
- 0.00
Key statistics
- Market cap
- 39.19M
- Enterprise value
- 28.45M
- Trailing P/E
- 0.00
- Forward P/E
- -0.72
- PEG ratio
- 0.00
- Price / sales
- 224.60
- Price / book
- 2.07
- EPS (TTM)
- -1.48
- Beta
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 174.47K
- Revenue growth
- 0.00%
- Free cash flow
- -4.45M
- Total cash
- 11.26M
- Total debt
- 523.92K
- Return on equity
- -71.91%
- Shares outstanding
- 12.87M
- Short % of float
- 1.23%
- 50-day average
- 3.25
- 200-day average
- 3.41
Analyst view
Consensus: none
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 31, 2021
Expected Mar 31, 2021. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 31, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2020 | Roth Capital | init | — | Buy |
| Nov 25, 2020 | Jefferies | main | — | Buy |
| Nov 25, 2020 | Needham | init | — | Buy |
| Nov 25, 2020 | Leerink Swann | init | — | Outperform |
| Nov 25, 2020 | JMP Securities | init | — | Market Perform |
| Nov 25, 2020 | Jefferies | init | — | Buy |
About Altamira Therapeutics Ltd.
Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase 1b clinical trial for the prevention of antipsychotic induced weight gain and drowsiness; and AM-301, a drug-free nasal spray for protection against airborne viruses and allergens, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Bermuda
- Website
- aurismedical.com
News
- Auris Medical Announces Launch of New Corporate Website
- 5 Reddit Penny Stocks to Watch That Are Moving Right Now
- Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19
- Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
- Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
- EARS Stock Price Increases Over 14% Pre-Market
- Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs
- EARS Stock Price: Over 9% Increase Pre-Market Explanation
- Auris Medical Holding to Present at LD Micro Invitational XI Conference
- Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo
Your note
Sign in to keep a note on EARS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ikarian Capital, LLC | 3.59% | 461,522 | 1.61M | Mar 30, 2021 |
| Boothbay Fund Management, LLC | 0.40% | 51,690 | 179.88K | Mar 30, 2021 |
| Citadel Advisors LLC | 0.36% | 45,729 | 159.14K | Mar 30, 2021 |
| Simplex Trading, LLC | 0.17% | 21,809 | 75.89K | Mar 30, 2021 |
| Geode Capital Management, LLC | 0.17% | 21,727 | 75.61K | Mar 30, 2021 |
| Envestnet Asset Management | 0.15% | 19,942 | 69.40K | Mar 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Micro Cap ETF | 0.24% | 30,685 | 109.55K | Jun 29, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.18% | 22,614 | 80.05K | Apr 29, 2021 |